Axsome Therapeutics Inc (AXSM) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of central nervous system (CNS) disorders. The company’s product candidates include AXS-05, which is being evaluated for treatment-resistant depression (TRD), major depressive disorder (MDD), and agitation associated with Alzheimer’s disease (AD); AXS-07, which is being developed for the treatment of migraine; AXS-12, which is being developed for the treatment of narcolepsy; AXS-14, which is being developed for the treatment of fibromyalgia; and AXS-09, which is being developed for the treatment of neurological disorders associated with certain metabolic disorders. Axsome Therapeutics was founded in 2012 and is based in New York, New York.
Axsome Therapeutics Inc (AXSM) is a clinical-stage biopharmaceutical company that develops therapies for the treatment of central nervous system (CNS) disorders. The company’s product candidates include AXS-05, which is being evaluated for treatment-resistant depression (TRD), major depressive disorder (MDD), and agitation associated with Alzheimer’s disease (AD); AXS-07, which is being developed for the treatment of migraine; AXS-12, which is being developed for the treatment of narcolepsy; AXS-14, which is being developed for the treatment of fibromyalgia; and AXS-09, which is being developed for the treatment of neurological disorders associated with certain metabolic disorders. Axsome Therapeutics was founded in 2012 and is based in New York, New York.